A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson’s Disease

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson’s Disease
Front Neurol. 2022 Jun 2;13:866502. doi: 10.3389/fneur.2022.866502. eCollection 2022.ABSTRACTBACKGROUND: Apathy is highly prevalent and disabling in Parkinson's disease (PD). Pharmacological options for its management lack sufficient evidence.OBJECTIVE: We studied the effects of safinamide on apathy in PD.METHODS: Prospective, 24-week, two-site, randomized, double-blind, placebo-controlled, parallel-group exploratory study in non-demented PD on stable dopaminergic therapy randomized 1:1 to adjunct safinamide (50 mg/day ... read more
Source: PubMedPublished on 2022-06-20By Jaime Kulisevsky